Selected Publications
Alexandra Weiss MD, Edward L Barnes MD MPH, Meenakshi Bewtra MD PhD MPH: A Practical Guide to the Use of Upadacitinib in Ulcerative Colitis and Crohn's disease American Journal of Gastroenterology : 2023.
James D Lewis, Lauren E Parlett, Michele L Jonsson Funk, Colleen Brensinger, Virginia Pate, Qufei Wu, Ghadeer K Dawwas, Alexandra Weiss, Brad D Constant, Maureen McCauley, Kevin Haynes, Jeff Yufeng Yang, Douglas E Schaubel, Andres Hurtado-Lorenzo, Michael David Kappelman: Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States Gastroenterology : 2023.
Weiss AH, Thanawala S, Tang H, Weber A, Buchner A.: Severity of inflammation as a risk factor for the development of colorectal dysplasia in PSC-IBD. (Poster Presentation) DDW : 2023.
Thanawala S, Weiss AH, Weber A, Tang H, Buchner A.: The role of liver transplant in the development of colorectal dysplasia in patients with PSC-IBD. (Poster Presentation) DDW : 2023.
Khan N, Pernes T, Weiss A, Trivedi C, Patel M, Medvedeva E, Xie D, Yang YX: Efficacy of Vedolizumab in a nationwide cohort of elderly inflammatory bowel disease patients Inflammatory Bowel Diseases : 2022 .
Weiss, A.H. and Buchner, A.M: Editorial: colorectal cancer in elderly-onset inflammatory bowel disease—what is the risk? Aliment Pharmacol Ther 56 (9): 1421-1422,2022.
Mahmud N, Weiss A, Trivedi C, Yang YXm Lewis J, Khan N: Risk of venous thromboembolism among patients with inflammatory bowel disease who contract severe acute respiratory syndrome Coronavirus 2 Gastroenterology 161 : 2021.
Weiss AH, Trivedi C, Pernes T, Patel M, Khan N: Incidence of infections and malignancy among elderly IBD patients exposed to vedolizumab, prednisone and mesalamine (Poster Presentation) DDW : 2021.
Weiss AH, Bhattacharya A, Ellison S, Osterman MT, Lichtenstein G: Lower Adalimumab trough levels are associated with higher risk of infectious complications in patients with IBD DDW : 2021.
Ellison S, Weiss AH, Bhattacharya A, Osterman MT, Lichtenstein G: Adalimumab trough concentration is not associated with adverse events in patients with IBD. DDW : 2021.
Academic Contact Information
51 North 39th Street
Philadelphia,
PA
19104
Patient appointments: 800-789-7366